Digital Companion Diagnostics Market Outlook 2026: Trends & Insights According to a newly published market research report by 24LifeSciences, global digital companion diagnostics market was valued at USD 5.2 billion in 2025 and is projected to reach USD 11.4 billion by 2034, growing at a compound annual growth rate (CAGR) of 10.5% during the forecast period. Digital companion diagnostics are specialized in vitro diagnostic tests that provide essential information for the safe and effective use of a corresponding therapeutic product. These advanced tools analyze specific biomarkers such as genetic mutations or protein expressions to identify patients who are most likely to benefit from a particular drug or who may be at increased risk of serious side effects. By enabling personalized treatment decisions, these diagnostics are fundamentally transforming patient care, particularly in complex therapeutic areas like oncology, where they guide targeted therapies and immunotherapies with unprecedented precision. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9120/digital-companion-diagnostics-market

Why Is the Global synthetic cannabinoid Market Growing? Investment Opportunities, Forecasts & Market Dynamics Synthetic cannabinoids are gaining prominence in neurological disorder treatments while facing scrutiny regarding recreational abuse. Pharmaceutical-grade variants now dominate development pipelines, with major players investing heavily in purified isomers for targeted therapies.. Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/275461/global-synthetic-cannabinoid-market-2024-975